Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Additional myelodysplasia-related genes mutations affected the clinical presentations and prognosis of patients with SRSF2/TET2 co-mutations

Michael Martin, Samuel Cockey, Veena Jajoo, Amy Li, Hailing Zhang, Le Wang, Lynn Moscinski, Richard Shao, Julie Li, Jinming Song

Blood (2025) 146 (Supplement 1): 2069.

https://doi.org/10.1182/blood-2025-2069

Published: 2025

Journal Articles

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, Najla Al Ali, Zachary Thompson, Nagehan Pakasticali, Jinming Song, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Onyee Chan

Blood (2025) 146 (Supplement 1): 4630.

https://doi.org/10.1182/blood-2025-4630

Published: 2025

Journal Articles

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Fatima Tuz Zahra, Ekrem Turk, Najla Al Ali, Sean Haney, Dimitrios Drekolias, Nicole Vincelette, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Seongseok Yun, Onyee Chan

Blood (2025) 146 (Supplement 1): 291.

https://doi.org/10.1182/blood-2025-291

Published: 2025

Journal Articles

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Ekrem Turk, Fernando Bustamante, Fatima Tuz Zahra, Yu-Han Chen, Rory Shallis, Onyee Chan, Samuel Reynolds, Alison Walker, Ling Zhang, Seongseok Yun, Jeffrey Lancet, David Sallman, Rami Komrokji, Jinming Song, Eric Padron, Gabriela Hobbs, Andrew Kuykendall, Zhuoer Xie

Blood (2025) 146 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2025-3815

Published: 2025

Journal Articles

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Onyee Chan, Kendra Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Nardelli, Jatinder Lamba, Jongphil Kim, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2025-5216

Published: 2025

Journal Articles

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy

Blood blood.2025029921.

https://doi.org/10.1182/blood.2025029921

Published: 2025

Includes: Supplemental data

Journal Articles

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Blood (2024) 144 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2024-210599

Published: 2024

Journal Articles

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Blood (2024) 144 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2024-201598

Published: 2024

Journal Articles

Comparison of the Clinicopathological Findings of Patients with SF3B1 / JAK2 , SF3B1 / Calr , or SF3B1 / MPL co-Mutations

Richard Shao, Hailing Zhang, Lynn C. Moscinski, Mohammad Omar Hussaini, Julie Li, Ahmed Arfa, Le Wang, Jinming Song

Blood (2024) 144 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2024-199880

Published: 2024

Journal Articles

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Onyee Chan, Kendra L. Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Ann Nardelli, Jatinder K. Lamba, Jongphil Kim, Jinming Song, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Rami S. Komrokji, Jeffrey E Lancet, David Sallman

Blood (2024) 144 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2024-206161

Published: 2024

Journal Articles

A Large Cohort Study of 412 Patients with SRSF2/TET2 Co-Mutated Myeloid Neoplasms: The Molecular Landscape and Clinical Outcomes

Samuel G Cockey, Hailing Zhang, Mohammad Omar Hussaini, Ling Zhang, Lynn C. Moscinski, Ethan Yang, Jinming Song

Blood (2023) 142 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2023-186967

Published: 2023

Journal Articles

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Ning Dong, Hailing Zhang, Jinming Song, Jamila Mammadova, Bijal D. Shah, Hayder Saeed, Ariel F. Grajales-Cruz, Leidy Lismeris Isenalumhe, Sameh Gaballa, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz, Julio C Chavez

Blood (2023) 142 (Supplement 1): 3138.

https://doi.org/10.1182/blood-2023-184779

Published: 2023

Journal Articles

Co-Existing ASXL1 and SF3B1 Mutations Carried Worse Outcome Than ASXL1 or SF3B1 Mutations Alone

Jinming Song, Lynn C. Moscinski, Ethan Yang, Mohammad Hussaini, Hailing Zhang

Blood (2022) 140 (Supplement 1): 4026–4027.

https://doi.org/10.1182/blood-2022-165241

Published: 2022

Journal Articles

Molecular Profiles and Clinical Features of Myeloproliferative Neoplasms Unclassifiable (MPN-U) with and without JAK2 / CALR / MPL Mutations

Curtis Gravenmier, Yumeng Zhang, Nagehan Pakasticali, Lynn C. Moscinski, Jinming Song, Ling Zhang

Blood (2022) 140 (Supplement 1): 12248–12249.

https://doi.org/10.1182/blood-2022-170665

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Blood (2021) 138 (23): 2435–2440.

https://doi.org/10.1182/blood.2021012536

Published: 2021

Includes: Supplemental data

Journal Articles

Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab

David Noyes, Melissa Alsina, Kenneth H. Shain, Rachid Baz, Taiga Nishihori, Jose Ochoa, Jinming Song, Jongphil Kim, Alexandra Achille, Jason Brayer

Blood (2021) 138 (Supplement 1): 2682.

https://doi.org/10.1182/blood-2021-151922

Published: 2021

Journal Articles

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T. Kuykendall, Eric Padron, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Jeffrey E. Lancet

Blood (2021) 138 (Supplement 1): 686.

https://doi.org/10.1182/blood-2021-150759

Published: 2021

Journal Articles

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

Jinming Song, MD PhD, Hailing Zhang, MD, Xiaohui Zhang, MD PhD, Mohammad Hussaini, MD, Ning Dong, MD, Lynn C Moscinski, Kenneth H. Shain, MD PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141656

Published: 2020

Journal Articles

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Mohammad O Hussaini, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD MS, David A. Sallman, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140885

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Additional myelodysplasia-related genes mutations affected the clinical presentations and prognosis of patients with SRSF2/TET2 co-mutations

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Comparison of the Clinicopathological Findings of Patients with SF3B1 / JAK2 , SF3B1 / Calr , or SF3B1 / MPL co-Mutations

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

A Large Cohort Study of 412 Patients with SRSF2/TET2 Co-Mutated Myeloid Neoplasms: The Molecular Landscape and Clinical Outcomes

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Co-Existing ASXL1 and SF3B1 Mutations Carried Worse Outcome Than ASXL1 or SF3B1 Mutations Alone

Molecular Profiles and Clinical Features of Myeloproliferative Neoplasms Unclassifiable (MPN-U) with and without JAK2 / CALR / MPL Mutations

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only